Swiss pharmaceutical giant Novartis (NYSE: NVS) reported double-digit growth in both revenue and net income for the second quarter (Q2) and first half (1H) of 2025. This performance underscores the strong momentum of its key growth brands.
Financial Highlights
- Q2 Revenue: Increased by 11% in constant currency to $14.1 billion, driven by a 12 percentage point volume increase. Price contributed 1 percentage point, and foreign exchange added another 1 percentage point, while generics erosion reduced growth by 2 percentage points.
- 1H25 Revenue: Advanced 13% in constant currency to $27.3 billion.
- Core Net Income: Reached $9.2 billion for 1H25, reflecting improved operating leverage.
Blockbuster Products
Four Novartis products achieved over $1 billion in quarterly sales:
- Entresto (sacubitril/valsartan): $2.36 billion, +22% cc (1H: $4.62 billion, +22%).
- Cosentyx (secukinumab): $1.63 billion, +6% cc (1H: $3.16 billion, +11%).
- Kisqali (ribociclib): $1.18 billion, +64% cc (1H: $2.13 billion, +60%).
- Kesimpta (ofatumumab): $1.08 billion, +33% cc (1H: $1.98 billion, +38%).
Capital Return Program
Novartis executed a significant share repurchase program in 1H25, repurchasing 48.8 million shares for $5.3 billion on the SIX second trading line. This completes the $15 billion buyback program initiated in July 2023. A total of 140.9 million shares have been retired under this plan.
Guidance
Management reaffirmed its guidance of high-single-digit sales growth for the full year 2025.-Fineline Info & Tech
